Streetbeat News

Analyst Ratings

FNV

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Franco-Nevada (NYSE:FNV) and raises the price target from $180 to $185.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:36 am

LUMO

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Lumos Pharma (NASDAQ:LUMO) and maintained a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:35 am

HL

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Hecla Mining (NYSE:HL) but lowers the price target from $10 to $9.25.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:34 am

VRDN

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN) but lowers the price target from $40 to $37.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:32 am

AQN

Algonquin Power (NYSE:AQN) reported Q2 earnings of $0.08 per share, missing the analyst consensus estimate of $0.11 by 27.27%. This is a 50% decrease from the same period last year. The company also reported quarterly sales of $627.90 million, missing the analyst consensus estimate of $635.26 million by 1.16%. This is a 0.58% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 10:31 am

PRAX

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Praxis Precision Medicine (NASDAQ:PRAX), but has lowered the price target from $15 to $7.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:31 am

GOSS

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Gossamer Bio (NASDAQ:GOSS) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:30 am

FDMT

HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $36.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:30 am

LIFE

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on aTyr Pharma (NASDAQ:LIFE) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:29 am

BCDA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioCardia (NASDAQ:BCDA) and maintained a $9 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:28 am